Is this biotech built for efficiency?
United Therapeutics develops and commercializes therapies, operating as a biotechnology business. The company’s activity centers on bringing its products to market and supporting their ongoing use. It runs at meaningful scale for a single-company biotech, with a market value around USD 23.2 billion. The business model is built around converting revenue into profit and cash, rather than funding operations through continual outside capital.
Can strong profits keep growing steadily?
FundamentalsFor 2025, reported in USD, revenue reached USD 3.18 billion, with EBIT of USD 1.49 billion and net income of USD 1.33 billion. That profit profile matches the current margin structure, with an 86.58% gross margin, a 45.29% operating margin, and a 40.61% net profit margin on a trailing basis. Revenue growth was 10.6% year over year.
The business also converted a large portion of operating profit into cash-like output, with a cash flow proxy of about USD 1.18 billion. Depreciation and amortization was USD 85.6 million, while capital spending was just USD 21.7 million, leaving USD 1.56 billion of cash on the balance sheet at period end. Trailing ROE of 19.24% shows how efficiently those earnings are being produced relative to equity.
Is the market underpricing steady returns?
DCF / MultiplesAt USD 547.06, the stock trades below the central DCF estimate but above the weaker scenario, and well below the stronger one. The pricing also aligns with a mid-teens EV/EBITDA of 14.40 and a high-teens P/E of 18.04, indicating that the market places weight on the durability of current earnings power.
Strong returns with limited reinvestment
TakeawayOperations are running with unusually high margins and strong cash conversion. Returns look good because the business needs little capital spending. The case works if revenue growth and margins hold together. It breaks if profitability compresses or cash generation fades.